Curatis Holding AG (SWX:CURN)

Switzerland · Delayed Price · Currency is CHF

17.50

-0.25 (-1.41%)

Oct 2, 2026, 5:30 PM CET

Market Cap	92.99M +30.2%
Revenue (ttm)	13.50M +32.8%
Net Income	-658.00K
EPS	-0.13
Shares Out	5.31M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,036
Open	17.50
Previous Close	17.75
Day's Range	16.20 - 17.80
52-Week Range	11.05 - 27.90
Beta	-0.81
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 21, 2026

About Curatis Holding AG

Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson’s disease, cyanide poisoning, digoxin toxicity, antihypotensive, bladder pain syndrome/intersticial cystitis, antibioticum, diagnostic ophthalmology, antiviral, ophtalmic/ antibioticum, gentamycin collage... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2002

Employees 9

Stock Exchange SIX Swiss Exchange

Ticker Symbol CURN

Full Company Profile

Financial Performance

In 2025, Curatis Holding AG's revenue was 10.80 million, an increase of 56.61% compared to the previous year's 6.90 million. Losses were -1.42 million, -67.41% less than in 2024.

Financial Statements